Omics Analysis Engine for Tumor Pathway Characterization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for guiding cancer treatment decisions rely heavily on genotyping tumor samples, which often lead to false-positive, false-negative, and non-relevant results due to the exclusive analysis of genetic mutations without considering transcriptional activity or functional context, resulting in inadequate treatment strategies.
Innovation Solution
A system and method for omics analysis that identifies shared pathway characteristics across various tumor samples by comparing tumor and matched normal tissue data, using transcriptomics to refine the analysis and generate molecular signatures independent of anatomical tumor type, enabling more accurate treatment recommendations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If genotyping of tumor samples is used to identify DNA mutations, then treatment decisions can be guided by molecular analysis, but false-positive and false-negative results occur due to lack of consideration of transcriptional activity and functional context
Solution Approach 1:
The patent combines genomics data (DNA mutations) with transcriptomics data (gene expression) to create a more comprehensive molecular profile. This merging of multiple data types allows for cross-validation of mutation findings and provides functional context, thereby reducing false positives and negatives while improving both measurement precision and reliability of treatment recommendations
Solution Approach 2:
The patent introduces an integrative analysis framework that acts as an intermediary between raw genomic data and treatment decisions. This framework processes multiple data layers (genomics, transcriptomics, pathway analysis) to produce refined molecular signatures, serving as a mediator that translates complex multi-omics data into reliable clinical recommendations
2Productivity
If exclusive analysis of genetic mutations is performed, then treatment guidance can be provided based on DNA changes, but functional context and compensatory mechanisms are not considered
Solution Approach 1:
The patent segments the molecular analysis into distinct but integrated layers: genomics analysis for mutation identification, transcriptomics analysis for expression validation, and pathway analysis for functional context. This segmentation allows systematic processing of complex data while preserving functional information through the hierarchical analysis structure
Solution Approach 2:
The patent adds another dimension to mutation analysis by incorporating transcriptomics data. Instead of relying solely on DNA mutation status (one dimension), the system evaluates both genomic alterations and their transcriptional consequences (second dimension), thereby recovering functional context information that would be lost in exclusive genotyping
3Ease of manufacture
If tumor samples are analyzed without considering transcriptional activity, then genotyping can be performed efficiently, but the actual expression and impact of genetic alterations remain unknown
Solution Approach 1:
The patent performs preliminary genotyping analysis to identify candidate mutations, then uses transcriptomics data to validate and refine these findings. The easy-to-perform genotyping serves as a preliminary screen, while subsequent expression analysis provides precise functional assessment, combining the advantages of both approaches
Data Source
AI summary
Omics patient data are analyzed using sequences or diff objects of tumor and matched normal tissue to identify patient and disease specific mutations, using transcriptomic data to identify expression levels of the mutated genes, and pathway analysis based on the so obtained omic data to identify specific pathway characteristics for the diseased tissue. Most notably, many different tumors have shared pathway characteristics, and identification of a pathway characteristic of a tumor may thus indicate effective treatment options ordinarily not considered when tumor analysis is based on anatomical tumor type only.